About Infinity Pharmaceuticals
Infinity Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers. The Company is also developing IPI-549, which is an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the gamma isoform of PI3K. In addition to duvelisib, the Company focuses to generate new product candidates for potential investigation in oncology. The Company also focuses on developing DYNAMO, CONTEMPO, BRAVURA, FRESCO, DYNAMO+R, DUO, SYNCHRONY and Duvelisib + Venetoclax.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: Biotechnology
- Exchange: NASDAQ
- Symbol: INFI
- CUSIP: 45665G30
- Previous Close: $2.44
- 50 Day Moving Average: $1.99
- 200 Day Moving Average: $1.55
- 52-Week Range: $0.84 - $6.97
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.74
- P/E Growth: -0.04
- Market Cap: $121.34M
- Outstanding Shares: 49,729,000
- Beta: 2.55
- Net Margins: 13.23%
- Return on Equity: -125.20%
- Return on Assets: -54.94%
Companies Related to Infinity Pharmaceuticals:
- Debt-to-Equity Ratio: 0.19%
- Current Ratio: 4.77%
- Quick Ratio: 4.77%
What is Infinity Pharmaceuticals' stock symbol?
Infinity Pharmaceuticals trades on the NASDAQ under the ticker symbol "INFI."
Where is Infinity Pharmaceuticals' stock going? Where will Infinity Pharmaceuticals' stock price be in 2017?
9 analysts have issued 12-month price targets for Infinity Pharmaceuticals' stock. Their forecasts range from $1.00 to $17.00. On average, they expect Infinity Pharmaceuticals' stock price to reach $5.00 in the next twelve months.
When will Infinity Pharmaceuticals announce their earnings?
Infinity Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February, 21st 2017.
What are analysts saying about Infinity Pharmaceuticals stock?
Here are some recent quotes from research analysts about Infinity Pharmaceuticals stock:
According to Zacks Investment Research, "Infinity, a development-stage biopharmaceutical company, is focused on the development of treatments for difficult-to-treat diseases. Estimates have been mostly stable ahead of the company’s Q3 earnings release. Infinity received a huge blow when AbbVie decided to terminate the collaboration for the development and commercialization of Infinity’s lead pipeline candidate, duvelisib. With the termination of this agreement, Infinity has regained the global rights to the candidate. Currently, the company is exploring strategic options for the duvelisib program, including a potential sale of the same. Therefore, the company has refrained from giving an update on the nature and timing of regulatory filing of the candidate. Infinity also announced restructuring plans and cut approximately 66% of its workforce. Infinity is also moving with its planned development of other immuno-oncology candidate IPI-549 in multiple solid tumors." (10/18/2016)
J P Morgan Chase & Co analysts commented, "Top-line pivotal data from phase 2 DYNAMO trial of duvelisib in refractory iNHL are expected early-3Q and is a key catalyst for Infinity this year (enabling a potential accelerated approval filing by YE16). While iNHL remains competitive among approved and developing therapeutics, based on physician feedback, we believe duvelisib has multiple potential shots at differentiation with respect to both the efficacy and / or safety profile. On efficacy, our physician feedback indicates that an overall response rate (ORR) of 65%+, particularly if driven by complete responses (CRs; 20%+) would be highly differentiated. Additionally, potential points of differentiation on the safety side include a lower overall rate of discontinuation, as well as lower rates of individual AEs such abnormal liver enzymes and diarrhea. Related to INFI shares heading into the DYNAMO readout, we believe the reward / risk is very favorable. Indeed, we see upside in INFI shares of 100-140% on efficacy and / or safety differentiation and downside of 25-30% (which is essentially cash, with no differentiation of the efficacy or safety side). We are adjusting our price target to $10 from prior $13 after taking a more conservative approach to the duvelisib model. Reiterate Overweight rating on INFI shares." (3/31/2016)
Who owns Infinity Pharmaceuticals stock?
Infinity Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Orbimed Advisors LLC (6.54%), Renaissance Technologies LLC (3.42%), Pinnacle Associates Ltd. (2.69%), FMR LLC (2.39%), State Street Corp (1.99%) and Oxford Asset Management (0.69%). Company insiders that own Infinity Pharmaceuticals stock include Adelene Q Perkins, Sujay Kango, Value Fund L P Biotechnology and Vito J Palombella.
Who sold Infinity Pharmaceuticals stock? Who is selling Infinity Pharmaceuticals stock?
Infinity Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Bogle Investment Management L P DE, State Street Corp and Pinnacle Associates Ltd..
Who bought Infinity Pharmaceuticals stock? Who is buying Infinity Pharmaceuticals stock?
Infinity Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Tudor Investment Corp Et Al, Oxford Asset Management and FMR LLC.
How do I buy Infinity Pharmaceuticals stock?
Shares of Infinity Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Infinity Pharmaceuticals stock cost?
One share of Infinity Pharmaceuticals stock can currently be purchased for approximately $2.42.